OncoCyte Corporation (OCX) CEO Ronnie Andrews on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/13/20
Oncocyte to Present DetermaIO™ Test Data at the 2020 Society for Immunotherapy of Cancer (SITC) ConferenceGlobeNewsWire • 11/09/20
Oncocyte Named One of the 2020 Best Places to Work in Orange County in Its First Year in Irvine, CAGlobeNewsWire • 10/28/20
Oncocyte Announces Third Quarter Growth of DetermaRx™ Physician Adoption and Testing VolumeGlobeNewsWire • 10/20/20
Oncocyte Agrees to Enter Licensing and Collaboration Agreement with Chronix BiomedicalGlobeNewsWire • 10/01/20
Oncocyte to Participate at the Lake Street Capital Markets 4th Annual Best Ideas Growth ConferenceGlobeNewsWire • 09/14/20
Oncocyte Receives Final Pricing Decision for DetermaRx™ Molecular Test for Lung Cancer from Centers for Medicare and Medicaid ServicesGlobeNewsWire • 09/09/20
Oncocyte Announces Addition of Experienced Healthcare Executive, Jennifer Carter, MD, MPH, MBA to Board of DirectorsGlobeNewsWire • 08/27/20
Oncocyte to Hold KOL Webinar Highlighting Clinical Data on Its DetermaIO™ Test for Immunotherapy Response PredictionGlobeNewsWire • 08/11/20
Oncocyte Corporation's (OCX) CEO Ronnie Andrews on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 07/30/20
Oncocyte Provides Corporate Update and Reports Second Quarter 2020 Financial ResultsGlobeNewsWire • 07/29/20
Oncocyte to Hold KOL Webinar Showcasing New Data and Real World Usage of DetermaRx™GlobeNewsWire • 07/23/20
Oncocyte to Report Second Quarter 2020 Financial Results on Wednesday, July 29GlobeNewsWire • 07/20/20
Oncocyte Announces Final Local Coverage Determination from Noridian Healthcare Solutions for DetermaRx™, Securing National Medicare Payment for the Test Starting August 2020GlobeNewsWire • 07/20/20
Oncocyte Announces Distribution Agreement with ProGenetics Ltd, Expanding Commercial Availability of DetermaRx™ to IsraelGlobeNewsWire • 07/16/20
Oncocyte Provides an Update on the Rapid Growth of DetermaRx™ Physician Adoption and Testing VolumeGlobeNewsWire • 07/14/20
Oncocyte: Despite The Bad Result Of DetermaDX The Comany Still Has Bullish PotentialSeeking Alpha • 07/02/20
Oncocyte: Despite The Bad Result Of DetermaDX The Company Still Has Bullish PotentialSeeking Alpha • 07/02/20
Oncocyte Transitions to Revenue Generation as Multiple Payers Begin DetermaRx™ ReimbursementsGlobeNewsWire • 06/15/20
Oncocyte Corporation (OCX) CEO Ronald Andrews on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/13/20
Oncocyte Provides Corporate Update And Reports First Quarter 2020 Financial ResultsGlobeNewsWire • 05/12/20